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1. Introduction 
Amyotrophic lateral sclerosis (ALS) is a fatal degenerative disease of motor neurons. About 
10 % of ALS cases are affected in a familial trait, a subset of which is caused by the mutation 
of Cu, Zn-superoxide dismutase (SOD1) gene (Rosen et al., 1993). Since the identification of the 
gene for familial ALS, research emphasis for ALS has been placed on uncovering the 
pathogenic mechanism of motor neuronal death by the disease-causing mutant SOD1. So far 
over 150 different mutations of SOD1 gene have been found in familial ALS patients, and 
they are scattered throughout the entire sequence of the gene regardless of specific 
functional domains. Transgenic mice that express mutant SOD1, but not wild type SOD1 nor 
SOD1 knockout mice, develop motor neuron disease, often while retaining normal 
dismutase activity (Gurney et al., 1994; Reaume et al., 1996). It means that mutant SOD1 
gains a new aberrant toxic function apart from the primary enzymatic function of the 
protein, which has remained uncertain to date. Although the nature of mutant SOD1 toxicity 
has not been fully determined, conformational abnormalities of mutant SOD1 protein are 
deeply involved in the pathogenesis of familial ALS (Chattopadhyay & Valentine, 2009). 
Moreover, recent studies suggest that the phenotype of sporadic ALS also might be 
regulated by the conformational change of wild type SOD1 (Bosco et al., 2010). I review the 
recent concept of neuronal toxicity by oxidatively-modified SOD1, which is closely related 
to its conformational change, in ALS pathogenesis. 
2. Cu-mediated oxidative toxicity by mutant SOD1 
SOD1 is a major metal-binding enzyme expressed constitutively in tissues, and converts 
pro-oxidant superoxide radicals to hydrogen peroxide and oxygen (Valentine et al., 2005). In 
a metal-coordinated state, SOD1 forms homodimer to accomplish its full enzymatic activity. 
Each subunit coordinates one atom each of Cu and Zn. Cu is necessary for the enzymatic 
activity, whereas Zn mainly works to maintain the stable structure of the protein. Because 
Cu is catalytically redox-active and has a potential to oxidize proteins including SOD1 itself, 
inappropriate reactivity of Cu coordinated in SOD1 can underlie the conformational change 
of mutant SOD1. Inversely, conformational change in mutant SOD1 may increase the 
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accessibility of substrates to Cu in the protein to generate reactive oxygen or nitrogen 
species. There is direct evidence that mutant SOD1 can promote abnormal pro-oxidant 
reactions cooperated with Cu. Mutant SOD1, unlike wild type SOD1, has a potential to 
generate hydroxyl radicals (Wiedau-Pazos et al., 1996; Yim et al., 1996) or peroxynitrite 
(Estevez et al., 1999) by Cu-dependent reaction in vitro, which can be inhibited by Cu 
chelators in cultured cells (Ghadge et al., 1997). Cu-mediated toxicity in mutant SOD1 is also 
reinforced with the reports that decreasing intracellular Cu, by treatment with Cu chelators 
or genetic reduction of Cu uptake, alleviates ALS phenotype in mutant SOD1 transgenic 
mice (Hottinger et al., 1997; Kiaei et al., 2004 ; Nagano et al., 2003; Tokuda et al., 2008). 
Moreover, metallothioneins, which bind Cu to prevent it from being pro-oxidant, are 
increased in the spinal cord of mutant SOD1 mice to attenuate the disease expression 
(Hashimoto et al., 2011; Nagano et al., 2001; Tokuda et al., 2007). These facts suggest that Cu-
mediated oxidative chemistry underlies the pathogenesis of familial ALS linked to 
mutations of SOD1 gene. 
On the other hand, the phenotype of mutant SOD1 mice was not rescued by genetic removal 
of the Cu chaperone for SOD1 (CCS), which incorporates Cu into the buried active site of 
SOD1 (Subramaniam et al., 2002). Furthermore, mutant SOD1 still induces the disease in 
transgenic mice even when the active copper-binding site is totally disrupted by multiple 
mutations (Wang et al., 2003). These findings had been taken as evidence against the 
hypothesis of aberrant Cu chemistry in the toxicity of mutant SOD1. However, the theory 
implicating Cu toxicity cannot be excluded since ectopic binding of Cu away from the active 
site, for example, could contribute to the pathogenesis. In fact, H46R mutant SOD1, which 
disrupts Cu binding at the active site, still has the ectopic binding of Cu (Liu et al., 2000). 
3. Increased affinity for Cu in mutant SOD1 
To clarify a possible aberrant interaction of mutant SOD1 with Cu outside the active site in 
the context of familial ALS, we characterized the affinity for Cu of the mutants by 
immobilized metal affinity chromatography (IMAC), a method that separates proteins based 
on their affinities with an immobilized metal such as Cu (Watanabe et al., 2007). Mutant 
SOD1 commonly exhibited an aberrant fraction with high affinity for Cu (SOD1HAC), in 
addition to that with low affinity for Cu (SOD1LAC) seen in wild type SOD1 as well. 
SOD1HAC was detected whether the mutants were expressed in yeasts, mammalian cells or 
spinal cords of transgenic mice, while an unknown cellular factor(s) other than SOD1 was 
needed for its generation (Nagano, unpublished data). We observed SOD1HAC even in 
H46R or G85R mutant SOD1, the mutants that do not efficiently incorporate Cu into the 
active site, and therefore the immobilized Cu is likely to interact with SOD1 outside the 
active site, on a solvent-facing surface of the protein. Considering that mutant SOD1 is 
separated into two distinct fractions (SOD1LAC and HAC) and the interaction of proteins 
on IMAC is determined by topology of metal-coordinating residues on solvent-facing 
surfaces (Porath et al., 1975), conformational transition from the native to non-native state is 
implied to be critical for the increased affinity for Cu in SOD1HAC. 
4. Monomerization of SOD1 by cysteine oxidation 
Then what is the determinant of conformational transition for SOD1HAC in mutant SOD1? 
Human SOD1 has four cysteine residues—Cys6, Cys57, Cys111 and Cys146—in a subunit. 
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Two of them (Cys57 and Cys146) form an intramolecular disulfide bond that maintains the 
rigid structure and enzymatic activity of SOD1 protein, whereas the remaining two (Cys6 
and Cys111) are present as cysteines having free sulfhydryl groups. Of the latter, Cys6 is 
deeply buried in the protein molecule and less accessible by substrates, while Cys111 is 
located on the surface of the protein near the dimer interface. Substitution of serine for 
Cys111 (C111S) is known to increase the structural stability and resistance to heat 
inactivation of wild type SOD1 (Lepock et al., 1990), implying that the mode of Cys111 may 
regulate the conformational state of mutant SOD1. H46R mutant SOD1, which has an 
ectopic binding to Cu as mentioned above, has been reported to bind the metal at Cys111 
(Liu et al., 2000). We hypothesized that Cys111 might be a candidate site in human SOD1 
that could enhance the coordination of the protein with immobilized Cu. Indeed, C111S 
substitution eliminated the increase of Cu binding in mutant SOD1. Moreover, the protein 
degradation assay in cell culture indicated that the decrease of SOD1HAC by C111S 
substitution well correlated with the stability of each mutant protein. That is, the stability 
was lower, the affinity for Cu was higher in mutant SOD1. In agreement with our findings, a 
previous report indicated that the decreased stability of mutant SOD1 correlated with its 
toxicity and the disease progression rate in familial ALS patients (Sato et al., 2005). 
Next, to examine whether other cysteine residues play the same role as Cys111 in mutant 
SOD1, we introduced C57S substitution into the protein. In contrast to the effect of C111S, 
C57S substitution rather increased Cu binding, and did not rescue the instability of the 
mutant. C57S substitution prevents the disulfide bond between Cys57 and Cys146, which is 
supposed to make SOD1 protein difficult to keep its structure and stabilize. Although the 
function of the disulfide bond in SOD1 is not fully elucidated, it could be related to either 
the dimerization of SOD1 or the metal binding process at the active site or both. Thus, 
mutant SOD1 with C57S may become conformationally further destabilized, exposing Cu-
interaction sites to enhance Cu affinity of the protein. 
We performed further biochemical characterization of SOD1HAC and determined what 
properties could cause its formation and toxicity. Since mutant SOD1 is known to 
susceptible to intramolecular disulfide reduction (Tiwari & Hayward, 2003), we employed a 
cysteine-modifying reagent to estimate the redox status of cysteine residues in SOD1HAC. 
We found that sulfhydryl groups of free cysteine residues, especially of Cys111, were 
oxidized in SOD1HAC while the residues remained reduced in SOD1LAC (Kishigami et al., 
2010). The intramolecular disulfide bond between Cys57 and Cys146 was unchanged in both 
components. 
The dimeric structure of SOD1 is destabilized in pathogenic SOD1 mutants (Furukawa & 
O'Halloran, 2005). We therefore investigated the dimer/monomer status of SOD1LAC and 
SOD1HAC using gel filtration chromatography. SOD1HAC eluted predominantly as a 
monomer, whereas SOD1LAC consisted of a dimer structure. It means that SOD1HAC 
formation is concordant with the loss of dimeric stability to form a monomer. 
We further employed nitrosoglutathione or hydrogen peroxide, cysteine-oxidizing reagents, 
in wild type SOD1 to mimic the sulfhydryl oxidation of Cys111 in SOD1HAC. We observed 
that the reaction actually modified Cys111, and engendered SOD1HAC. Moreover, we saw 
that Cys111-modified wild type SOD1 lost its dimeric conformation and mainly consisted of 
a monomer in SOD1HAC. Conversely, intersubunit crosslinking between Cys111 of each 
subunit prevented mutant SOD1 from monomerizing and developing SOD1HAC. These 
results mean that Cys111 is labile to be oxidized by endogenous agents such as 
www.intechopen.com
  
Amyotrophic Lateral Sclerosis 
 
304 
nitrosoglutathione or hydrogen peroxide in familial ALS-linked mutant SOD1, which is the 
first step for the substantial monomerization of the protein and increase of the Cu affinity 
probably by exposing a Cu-accessible interface of the dimer. 
5. Oxidative stress by cysteine-oxidized SOD1 
In case that SOD1 is monomerized through conformational destabilization mediated by 
Cys111 oxidation, Cu coordinated at the ectopic binding site can be redox-active. To see 
whether SOD1HAC causes an aberrant redox reaction, we measured thiol oxidase activity, a 
Cu-dependent activity that is reported in human SOD1 (Winterbourn et al., 2002). We found 
that mutant or Cys111-oxidized wild type SOD1 developed the thiol oxidase activity when it 
was loaded with Cu, and that the activity was decreased by C111S substitution or 
intermolecular crosslinking of Cys111. Because SOD1 modified at Cys111 possesses the thiol 
oxidase activity, it is unlikely that Cys111 itself is the direct binding site for Cu. These 
results indicate that cysteine-oxidized SOD1 may exert the potentially toxic pro-oxidant 
activity through ectopic binding of Cu to SOD1HAC at a site within the dimer interface, 
which becomes exposed upon the dissociation of SOD1. The thiol oxidase activity of mutant 
SOD1 can promote oxidative stress because of the exhaustion of glutathione, the major free 
thiol and antioxidant. The activity may also oxidize cysteine residues of other proteins, 
deteriorating various cell functions (Fig. 1). 
 
 
 
 
 
 
 
 
 
Fig. 1. Proposed model of mutant SOD1 toxicity. Modification of Cys111 leads to 
dissociation of SOD1 dimers into monomers. Cu, either resulting from rearrangement of the 
active site or from an external source, becomes ectopically bound to the former dimer 
interface surface, where it can now catalyze thiol oxidase activity (Kishigami et al., 2010). 
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6. Role of cysteine-oxidized mutant SOD1 in familial ALS 
What is the role of Cys111 modification on the neuronal toxicity by mutant SOD1? In the 
spinal cords of familial ALS patients and mutant SOD1 transgenic mice, degenerating motor 
neurons contain SOD1-positive inclusion bodies, suggesting that mutant SOD1 is 
conformationally misfolded and subject to aggregate (Chattopadhyay & Valentine, 2009). As 
seen in other neurodegenerative diseases, abnormal protein accumulation in neurons can 
impair their cellular functions such as axonal transport (Tateno et al., 2009), oxidative 
phosphorylation in mitochondria and protein degradation machinery. 
Various factors can cause conformational rearrangement or misfolding of mutant SOD1, 
including decreased metallation (Hayward et al., 2002), hydrophobicity (Tiwari et al., 
2005) and reduction of repulsive charge (Sandelin et al., 2007). Modification of amino acid 
residues, especially by oxidative stress, can be a critical factor to enhance the misfolding 
of mutant SOD1 (Rakhit & Chakrabartty, 2006). Cysteine is in particular susceptible to 
oxidative modification, since its sulfhydryl moiety is readily attacked by redox active 
substrates such as glutathione or peroxides to form S-S or S-O covalent modification. 
Sulfhydryl groups also crosslink each other to form intra- or inter-molecular disulfide 
bond, which have important roles to maintain or disrupt physiological conformation of 
proteins. Oxidative reactivity and modification of Cys111, such as glutathionylation 
(Kajihara et al., 1988; Schinina et al., 1996) and peroxidation (Fujiwara et al., 2007), was 
documented with human or chick wild type SOD1, although the effect of which on the 
enzymatic activity or dimer stability had not been determined. Because Cys111 is located 
on the edge of the dimer interface of each subunit, the modification of Cys111, especially 
when a large molecule such as glutathione is adducted to the residue, can interrupt the 
dimer contact at the interface stereochemically and cause the dissociation of SOD1. 
Molecular dynamics simulations of SOD1 imply that the region including Cys111 is 
important for the residue interaction network in the protein, and likely to affect the dimer 
interface through the network and may disrupt their coupled motions (Khare & 
Dokholyan, 2006). In fact, glutathionylation of Cys111 has been confirmed with native 
human SOD1 in erythrocytes (Nakanishi et al., 1998; Wilcox et al., 2009), and it was noted 
that the modification caused SOD1 liable to monomerize and decrease its enzymatic 
activity (Wilcox et al., 2009). The SOD1 monomer is prone to form aggregates that might 
be the origin of intracellular inclusions found in motor neurons with SOD1-linked familial 
ALS. Supporting that, Cys111-peroxidized SOD1 was detected in the neuronal inclusions 
of mutant SOD1 mice (Fujiwara et al., 2007). 
Oxidative modification of cysteine residues, including Cys111, is also possible to be 
involved in the aggregation process of mutant SOD1. High molecular weight dimers and 
multimers of mutant SOD1 can be detected in the spinal cords of transgenic mice in 
parallel to the disease onset (Deng et al., 2006; Furukawa et al., 2006). They are detergent-
insoluble and reversed by reductants, supposing that disulfide-mediated crosslinking at 
cysteine residues is a major factor for mutant SOD1 to form aggregates and ALS 
phenotype. Cysteines forming the intramolecular disulfide bond (Cys57 and Cys146) are 
possibly involved in the crosslinking, since the disulfide bond between the residues is 
labile to be reduced (Tiwari & Hayward, 2003) and cause aberrant oxidation in mutant 
SOD1. The disulfide-reduced mutant SOD1 is actually enriched in the spinal cord of 
transgenic mice (Jonsson et al., 2006). The reduced form of mutant SOD1 can also 
translocate into the intermembrane space of mitochondria cooperated by CCS (Field et 
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al., 2003), which may be components of aggregates in mitochondria (Deng et al., 2006; 
Ferri et al., 2006) and harmful to the mitochondrial function. However, intermolecular 
disulfide bonds mediated at free cysteines (Cys6 and Cys111) can also be components of 
the detergent-insoluble SOD1 aggregates (Banci et al., 2007; Niwa et al., 2007). In either 
case, apo SOD1 is more prone to the disulfide-linked oxidative aggregation than holo 
SOD1 (Banci et al., 2007; Furukawa & O'Halloran, 2005). That is in concert with the 
notion that immature SOD1 is the pathogenic species in familial ALS (Seetharaman et al., 
2009). 
It is still controversial whether the cysteine-mediated misfolding or aggregation of mutant 
SOD1 is the origin of the protein’s toxicity. Removal of free cysteines, especially of Cys111, 
strongly reduced the ability of mutant SOD1 to form disulfide crosslinking and aggregates, 
and improved cell viability in cultured cells (Cozzolino et al., 2008; Niwa et al., 2007). 
Moreover, glutaredoxins, which specifically catalyze the reduction of protein-SSG-mixed 
disulfides, significantly increased the solubility of mutant SOD1 and protected neuronal 
cells (Cozzolino et al., 2008; Ferri et al., 2010). On the other hand, the intermolecular 
disulfide binding at cysteines is shown to have a limited effect on the aggregation of mutant 
SOD1 (Karch & Borchelt, 2008). Even in this case, Cys111-modified mutant SOD1 may cause 
neuronal toxicity independently of the aggregation, by oxidative stress such as thiol oxidase 
activity we have shown (Kishigami et al., 2010). 
7. Role of cysteine-oxidized wild type SOD1 in sporadic ALS 
In sporadic ALS, there had been no direct evidence that SOD1 was involved in the 
pathogenesis of the disease, except that some mutations of SOD1 gene expressed familial 
ALS in a low penetration rate with seemingly ‘sporadic’ cases. The link between SOD1 and 
sporadic ALS was first introduced by the detection of SOD1 specifically modifiable with a 
chemical compound commonly in familial and sporadic ALS, although the molecular basis 
for it has not been determined in detail (Gruzman et al., 2007). It indicates that a similar 
conformational change in mutant and wild type SOD1 can trigger the phenotype of familial 
and sporadic ALS in common. In in vitro study, wild type SOD1 acquires toxic properties of 
mutant SOD1 through oxidation by hydrogen peroxide (Ezzi et al., 2007), implying that 
cysteine-oxidized wild type SOD1 may be a contributor to motor neuronal death in sporadic 
ALS. 
Recently, a conformation-specific antibody generated against misfolded mutant SOD1 has 
been shown to recognize wild type SOD1 only when the protein was sulfonylated (-SO3H) at 
Cys111, and the antibody immunostained motor neurons in the spinal cords of sporadic 
ALS patients, but not of SOD1-unrelated familial ALS patients or controls (Bosco et al., 
2010). Chemically oxidized or purified wild type SOD1 from sporadic ALS spinal cords 
inhibited kinesin-based fast axonal transport as did mutant SOD1, supposing that Cys111-
mediated conformational change or misfolding of SOD1 is a shared pathological 
denominator of familial and sporadic ALS. Interestingly, most of the sporadic ALS-derived 
toxic SOD1 was soluble and non-aggregated, meaning that misfolding or monomerization is 
sufficient for SOD1 to gain the toxic property such as oxidative insult we have shown in 
mutant and wild type SOD1 (Kishigami et al., 2010). Further studies in vivo will be required 
to clarify the detailed mechanism of SOD1 toxicity mediated by oxidation of cysteine 
residues including Cys111. 
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8. Conclusion 
The findings mentioned above indicate that oxidative modification of SOD1 at cysteine 
residues is a critical factor to contribute to the oxidative stress, inclusion pathology and 
degeneration of motor neurons commonly to familial and sporadic ALS. Based on them, 
steric inhibition of cysteine oxidation, monomerization or exposure of the dimer interface 
can be the first-line treatment strategy of this incurable disease. 
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